CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients
Clinical trial NCT04990557 · UNKNOWN
Trial details
- NCT number
- NCT04990557
- Sponsor
- Mahmoud Ramadan mohamed Elkazzaz
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-01
- Primary completion
- 2022-11-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.